Skip to main content
SearchLoginLogin or Signup

Review 1: "Inhibition of SARS-CoV-2 infection in human cardiomyocytes by targeting the Sigma-1 receptor disrupts cytoskeleton architecture and contractility"

This preprint uses iPS-derived cardiomyocytes to investigate the role of Sigma-1 Receptor (S1R) during SARS-CoV-2 infection and finds S1R antagonism reduces SARS-CoV-2 replication at the expense of cardiomyocyte function. Reviewers deem these claims reliable.

Published onMar 29, 2021
Review 1: "Inhibition of SARS-CoV-2 infection in human cardiomyocytes by targeting the Sigma-1 receptor disrupts cytoskeleton architecture and contractility"
1 of 2
key-enterThis Pub is a Review of
Inhibition of SARS-CoV-2 infection in human cardiomyocytes by targeting the Sigma-1 receptor disrupts cytoskeleton architecture and contractility

ABSTRACTHeart dysfunction, represented by conditions such as myocarditis and arrhythmia, has been reported in COVID-19 patients. Therapeutic strategies focused on the cardiovascular system, however, remain scarce. The Sigma-1 receptor (S1R) has been recently proposed as a therapeutic target because its inhibition reduces SARS-CoV-2 replication. To investigate the role of S1R in SARS-CoV-2 infection in the heart, we used human cardiomyocytes derived from induced pluripotent stem cells (hiPSC-CM) as an experimental model. Here we show that the S1R antagonist NE-100 decreases SARS-CoV-2 infection and viral replication in hiPSC-CMs. Also, NE-100 reduces cytokine release and cell death associated with infection. Because S1R is involved in cardiac physiology, we investigated the effects of NE-100 in cardiomyocyte morphology and function. We show that NE-100 compromises cytoskeleton integrity and reduces beating frequency, causing contractile impairment. These results show that targeting S1R to challenge SARS-CoV-2 infection may be a useful therapeutic strategy but its detrimental effects in vivo on cardiac function should not be ignored.

RR:C19 Evidence Scale rating by reviewer:

  • Reliable. The main study claims are generally justified by its methods and data. The results and conclusions are likely to be similar to the hypothetical ideal study. There are some minor caveats or limitations, but they would/do not change the major claims of the study. The study provides sufficient strength of evidence on its own that its main claims should be considered actionable, with some room for future revision.



The manuscript by Salerno et al deals with the anti-SARS-CoV-2 action of a reference sigma-1 receptor antagonist, NE100, in human cardiomyocytes. In particular, it shows how, in these cells, NE100 reduces SARS-CoV-2 infection and viral replication, reduces cell death associated with infection, and attenuates the release of inflammatory cytokines (IL6 and IL8). However, contractility is importantly reduced, likely because of a verified disruption of the cytoskeleton architecture.

The paper is very well structured, supported by evidence, and in my opinion deserves to be published. Nevertheless, another sigma-1 receptor reference compound should be used, in order to more confidently correlate the effects we see with the interaction of NE100 with sigma-1 receptors, at least in a couple of assays that the authors consider more representative. Alternatively, experiments with sigma-1 receptors KO cells could be conducted. This is particularly important as recent literature, that has to be cited (Gordon et al, Science 2020, 370, 1181) because of its breakthrough findings, shows how the KO and KD of sigma-1 receptors drastically reduce SARS-CoV-2 infection. However, no clear correlation between sigma-1 receptor affinity of the ligands tested and antiviral activity is observed in the cited paper. While unraveling sigma-1 receptors as crucial host dependency factors for the virus infection, the paper by Gordon et al. also points out as the effect of sigma ligands has to be extensively studied, and can go beyond the definition of sigma-1 agonist and antagonist. Therefore, it is of crucial importance to further support that NE100 antiviral action is mediated by sigma-1 receptor, in order to confidently direct research efforts towards investigations of the sigma-1 receptors as a druggable target against the coronavirus responsible for the COVID-19 pandemic (and likely other viruses).

Overall, results presented in this manuscript support this role of sigma-1 receptor (but can strengthen it more) and provide an important alert about the toxic cardiac effects that sigma-1 ligands, such as NE100, may have, while also providing a convenient model to study these cardiac effects.

No comments here
Why not start the discussion?